IN THE SPOTLIGHT

Case Report: Successful late-line pralsetinib treatment in an ALK-rearranged lung adenocarcinoma patient with KIF5B-RET fusion resistant to alectinib

Case Report: Successful late-line pralsetinib treatment in an ALK-rearranged lung adenocarcinoma patient with KIF5B-RET fusion resistant to alectinib

Alectinib-Bevacizumab Combo Demonstrates Activity in Treatment-Naïve, ALK-Rearranged, Metastatic NSCLC

Alectinib-Bevacizumab Combo Demonstrates Activity in Treatment-Naïve, ALK-Rearranged, Metastatic NSCLC

Neoadjuvant Alectinib Effective, Tolerable in Late-Stage ALK-Positive NSCLC

Neoadjuvant Alectinib Effective, Tolerable in Late-Stage ALK-Positive NSCLC

Sarah Waliany: Honored to Receive Young Investigator Award for Research on ALK Inhibitors in NSCLC

Sarah Waliany: Honored to Receive Young Investigator Award for Research on ALK Inhibitors in NSCLC

Influence of ALK versions upon brain metastasis and treatment method reaction throughout innovative NSCLC individuals along with oncogenic ALK blend.

Influence of ALK versions upon brain metastasis and treatment method reaction throughout innovative NSCLC individuals along with oncogenic ALK blend.

Case Report: ALK-rearranged mesenchymal neoplasms with S100 and CD34 co-expression: additional cases with distinct characteristics

Case Report: ALK-rearranged mesenchymal neoplasms with S100 and CD34 co-expression: additional cases with distinct characteristics

Alectinib approved in Italy as adjuvant therapy for NSCLC Alk-positive

Alectinib approved in Italy as adjuvant therapy for NSCLC Alk-positive

Alectinib-Bevacizumab Combo Demonstrates Activity in Treatment-Naïve, ALK-Rearranged, Metastatic NSCLC

Alectinib-Bevacizumab Combo Demonstrates Activity in Treatment-Naïve, ALK-Rearranged, Metastatic NSCLC

Lorlatinib Yields Distinguishing CNS Benefit in ALK-Positive NSCLC

Lorlatinib Yields Distinguishing CNS Benefit in ALK-Positive NSCLC

Lung Cancer Was a Death Sentence. Now Drugs Are Saving Lives.

Lung Cancer Was a Death Sentence. Now Drugs Are Saving Lives.